Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

AM-Pharma B.V.

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of severe inflammatory diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in severe Ulcerative Colitis, AM-Pharma will replace bovine Alkaline Phosphatase with its proprietary recombinant form of human Alkaline Phosphatase. This recombinant material will be used in future trials and for commercialization. Following series D fundraising of €29.2M, AM-Pharma will finalize the GMP production of recombinant AP and its further development through phase II in patients. *


Period Start 2001-07-01 existent
  Group AM-Pharma (Group)
Product Industry biopharmaceutical
Region Region Bunnik
  Country Netherlands
  Street 6 Rumpsterweg
  City 3981 Bunnik
  Tel +31-30-228-9222
    Address record changed: 2018-07-24
Basic data Employees B: 11 to 50 (2006-01-29)
    * Document for �About Section�: AM-Pharma B.V.. (9/13/11). "Press Release: AM-Pharma Raises €29.2m in Series D Financing". Bunnik.
Record changed: 2020-04-30


Picture [iito] Männer Ballett 650x80px

More documents for AM-Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top